A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 278 participants.
Also called NCT04450394
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 278 participants
- Sponsor
- Registry
-
NCT04450394 -
2019-003339-53
-
- Other papers using this trial's data
- Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Germany, Poland, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT04450394. Randomized; no masking; primary purpose treatment. Start 2020-07-01 (actual); primary completion 2021-10-08 (actual). Results posted on 2022-11-02.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- LY3209590
- Intervention (Drug)
- Insulin Degludec
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct04450394- Content hash
d57b2509e4e9ba85c2bdc9d6611c72ddf3837bfc921505a2807a8a19549759f1